AngioDynamics maintained at outperform by RBC

RBC Capital Markets analyst Phil Nalbone kept AngioDynamics Inc. at outperform, speculative risk, ahead of the company's release of fourth-quarter results. The analyst's channel checks reveal strong demand and market share gains for AngioDynamics' broad product line of minimally-invasive devices for the treatment of peripheral vascular disease. Management's first-time guidance for full-year 2007 should be upbeat. Shares of the Queensbury, N.Y.-based medical device company were up $1.45, or 6.53%, at $23.65, on volume of 118,218 shares versus the three-month running average of 126,603 shares. (Nasdaq: ANGO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.